BIOTRON LIMITED — Board/Management Information 2025

Dec 22, 2025

==> picture [230 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: mmora@miscorp.com.au Website: www.biotron.com.au

23 December 2025

The Manager Companies ASX Limited 20 Bridge Street SYDNEY NSW 2000

(3 pages by email)

Dear Sir / Madam

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of Biotron Limited (‘Biotron’ or the ‘Company’) is pleased to announce the appointment of Dr Paul Kasian as Non-Executive Director, effective today.

Dr Paul Kasian has over 30 years of experience in high level executive and non-executive leadership roles, demonstrating domestic and international success in creating and building businesses. He has strong skills in business management/development, leadership and board level decision making. He is currently Chairman of Diamond Key International. As well as having a PhD in Microbiology, he is a graduate from the Australian Institute of Company Directors.

Dr Kasian’s previous roles include: Executive Chairman at Sedarex Ltd; Executive Chairman at Genetic Technologies Ltd; Non Executive Director (and Chairman of the Audit and Risk Committee) at Atomo Diagnostics Ltd; Chairman at IODM Ltd; Executive Chairman at Zucero Therapeutics Ltd; Chief Investment Officer at HSBC Asset Management Australia.

Biotron’s Chairman, Michael Hoy said “We are delighted with the appointment of someone with the calibre of Paul as a Non-Executive Director of the Company. He brings a wealth of knowledge and experience to Biotron.”

In accordance with Listing Rule 3.19A, I attach an Appendix 3X, Initial Director's Interest Notice, for Paul Kasian.

This announcement has been approved by Biotron Board of Directors.

Yours faithfully,

==> picture [114 x 48] intentionally omitted <==

Michelle Miller Managing Director

pjn12831

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	BIOTRON LIMITED
ABN	60 086 399 144

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	PAUL KASIAN
Date of appointment	23 DECEMBER 2025

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

N/A

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest. Yongala Invetments Pty Ltd <Kasian Super Fund (Where the director holds a beneficial interest) Yongala Invetments Pty Ltd (Where the director holds a beneficial interest)	Number & class of Securities 31,060,384 Ordinary fully paid shares 31,060 Performance Shares 42,073,154 Ordinary fully paid shares 42,074 Performance Shares

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

• See chapter 19 for defined terms.

11/3/2002

Appendix 3X